跳转至内容
Merck

A1500000

硫唑嘌呤

European Pharmacopoeia (EP) Reference Standard

别名:

6-[(1-甲基-4-硝基-1H-咪唑-5-基)硫代]-1H-嘌呤

登录查看公司和协议定价

选择尺寸

100 MG
$225.00

$225.00


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
100 MG
$225.00

About This Item

经验公式(希尔记法):
C9H7N7O2S
CAS号:
分子量:
277.26
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

$225.00


请联系客服了解存货情况

获取大包装报价

等級

pharmaceutical primary standard

API 家族

azathioprine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

Cn1cnc(c1Sc2ncnc3[nH]cnc23)[N+]([O-])=O

InChI

1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)

InChI 密鑰

LMEKQMALGUDUQG-UHFFFAOYSA-N

基因資訊

human ... PPAT(5471)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Azathioprine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Eliza Prefontaine et al.
The Cochrane database of systematic reviews, (6)(6), CD000545-CD000545 (2010-06-18)
The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treatment of active Crohn's disease were conflicting and controversial. A meta-analysis was performed to assess the effectiveness of these drugs for the induction of remission
Jeffrey J Bidinger et al.
Journal of the American Academy of Dermatology, 65(1), 184-191 (2011-04-19)
Azathioprine (AZA) hypersensitivity syndrome is a rare side effect that typically occurs early in the initiation of therapy and may include a cutaneous eruption. It is often under-recognized because it mimics infection or disease exacerbation. Until recently, the cutaneous findings
Mandy E Schram et al.
Archives of dermatology, 147(4), 474-488 (2011-04-13)
To summarize evidence regarding the effectiveness, efficacy, and safety of off-label azathioprine use in dermatology. We searched the MEDLINE (1950-2009), EMBASE (1980-2009), and CENTRAL (1996-2009) databases on October 9, 2009. The main search terms were azathioprine and its synonyms. No
D Dooremont et al.
Acta gastro-enterologica Belgica, 76(3), 342-346 (2013-11-23)
We report 3 male IBD patients (2 Crohn's Disease, 1 Ulcerative Colitis) developing thrombocytopenia and splenomegaly on azathioprine treatment. All patients were diagnosed with significant portal hypertension due to histological proven nodular regenerative hyperplasia (NRH) of the liver. In two
Anne Bourrier et al.
Current drug targets, 14(12), 1471-1479 (2013-04-12)
Azathioprine is an efficient maintenance treatment of IBD, able to maintain a complete clinical and anatomical remission in about one third of patients. However there are concerns regarding its long term tolerance, particularly myelosuppression and malignancy. Azathioprine is not required

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门